Literature DB >> 18220295

Secondary social anxiety in hyperkinesias.

Erguvan Tugba Ozel-Kizil1, M Cenk Akbostanci, Halise D Ozguven, Esref Cem Atbasoglu.   

Abstract

This is a comparison study that is aimed to investigate and compare the frequency and severity of secondary social anxiety disorder (SAD) in patients with hyperkinesias, which is associated with a significant sense of disfigurement and compromised social interaction. Patients with hemifacial spasm (n = 20), cervical dystonia (n = 20), and essential tremor (n = 20) were evaluated by SCID-I, Liebowitz Social Anxiety Scale, Hamilton Anxiety and Depression Rating Scales, and Sheehan Disability Scale. The DSM-IV H criterion excluding social anxiety related to a medical condition was disregarded for the diagnosis of secondary SAD. The control group (n = 60) consisted of matched healthy subjects. The frequency of the diagnosis and severity of symptoms were compared and associations with sociodemographic and clinical factors were explored. There was no difference between three patient groups in terms of the frequency or the severity of secondary SAD. Younger age and depressive symptoms were associated with the severity of secondary SAD, while severity or duration of the movement disorder or social disability was not. This study revealed a high frequency of secondary SAD in hyperkinesias, emphasizing the need for psychiatric assessment, especially for younger and depressed patients, who seem to be at greater risk. 2007 Movement Disorder Society

Entities:  

Mesh:

Year:  2008        PMID: 18220295     DOI: 10.1002/mds.21764

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  11 in total

1.  [Botulinum toxin therapy for spasmodic torticollis: medical and non-medical adjunct treatment].

Authors:  B Leplow; M Böttcher; R Schönfeld
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

Review 2.  Essential tremor--a neurodegenerative disorder associated with cognitive defects?

Authors:  Félix Bermejo-Pareja
Journal:  Nat Rev Neurol       Date:  2011-04-12       Impact factor: 42.937

Review 3.  Psychiatric comorbidities in dystonia: emerging concepts.

Authors:  Mateusz Zurowski; William M McDonald; Susan Fox; Laura Marsh
Journal:  Mov Disord       Date:  2013-06-15       Impact factor: 10.338

4.  The cognitive side of essential tremor: what are the therapeutic implications?

Authors:  Sarah C Janicki; Stephanie Cosentino; Elan D Louis
Journal:  Ther Adv Neurol Disord       Date:  2013-11       Impact factor: 6.570

5.  Essential Tremor is not Only a Movement Disorder; Its Relationship with Sleep and Anxiety.

Authors:  Bilgehan Atılgan Acar; Türkan Acar
Journal:  Noro Psikiyatr Ars       Date:  2018-09-17       Impact factor: 1.339

6.  Use of antiepileptic drugs for hyperkinetic movement disorders.

Authors:  A Siniscalchi; L Gallelli; G De Sarro
Journal:  Curr Neuropharmacol       Date:  2010-12       Impact factor: 7.363

7.  Treatment satisfaction with botulinum toxin: a comparison between blepharospasm and cervical dystonia.

Authors:  Bernd Leplow; Anna Eggebrecht; Johannes Pohl
Journal:  Patient Prefer Adherence       Date:  2017-09-14       Impact factor: 2.711

8.  Sexual dysfunction in cervical dystonia and blepharospasm.

Authors:  M Marek; M Grobe-Einsler; J R Bedarf; B Wabbels; S Paus
Journal:  Neuropsychiatr Dis Treat       Date:  2018-10-26       Impact factor: 2.570

9.  Subjective versus objective symptom intensities ratings in cervical dystonia and hemifacial spasm across a botulinum neurotoxin cycle.

Authors:  Julia Wöllner; David Weise; Bernd Leplow
Journal:  Brain Behav       Date:  2021-01-05       Impact factor: 2.708

10.  Psychiatric associations of adult-onset focal dystonia phenotypes.

Authors:  Brian D Berman; Johanna Junker; Erika Shelton; Stefan H Sillau; H A Jinnah; Joel S Perlmutter; Alberto J Espay; Joseph Jankovic; Marie Vidailhet; Cecilia Bonnet; William Ondo; Irene A Malaty; Ramón Rodríguez; William M McDonald; Laura Marsh; Mateusz Zurowski; Tobias Bäumer; Norbert Brüggemann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-04-24       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.